BioSpace News Archive

- Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in four upcoming investor and industry conferences. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, is expected to be discussed in each conference. Maryland Life Sciences Bio Innovation Conference Date: Monday, October 5, 2020 Time: 10:25 -11:25 a.m. ET

Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into Systemic Mastocytosis patients in 1H21 Abstract selected for oral presentation at CTOS 2020 New data from the Phase 1/2 clinical trial of CGT9486 in combination with sunitinib in patients with advanced GIST to be presented [05-October-2020]

Canadians have saved close to $2-billion in prescription drug costs during the first half of the five-year agreement between the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA).

HistoSonics, developer of a non-invasive platform and novel sonic beam therapy, announced today that it has received approval of an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to b

Aetna®, a CVS Health® company, announced its 2021 Medicare offerings, featuring increased integration with CVS Health; expanded and differentiated Medicare Advantage plan options, including HMO and Dual Eligible Special Needs Plan offerings in new states; new Aetna Medicare Eagle™ plans designed especially for Veterans; and the lowest premium standalone prescription drug plan product in all 50 states and D.C.

Joseph Duffy PhD brings 20+ years of small molecule discovery chemistry and operations to his role as SVP Chemistry of Skyhawk Therapeutics, Elliot Ehrich MD brings 20+ years of clinical development for novel pharmaceuticals to his role as Chief Medical Officer of Skyhawk Therapeutics, and Rob Hershberg MD-PhD with 25+ years of biotech and pharma experience has jo

The Plasma Protein Therapeutics Association is proud to mark the launch of the eighth annual International Plasma Awareness Week, which will run until October 9.

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that the company will present at two virtual investor conferences in October 2020.

- Concurrent development program compares Kodiak’s long-acting anti-VEGF antibody biopolymer conjugate KSI-301 to standard of care in all major retinal disease indications: wet AMD, DME, and RVO. - Kodiak also announces completion of U.S. patient enrollment in DAZZLE, its ongoing Phase 2b/3 study of KSI-301 in wet AMD. - Phase 1b durability data continue to improve as they mature further: 72% of wet AMD patients and 79% of DME patients have now achieved a 6-month or longer tr

The Gold Standard Diagnostics Group (GSD) today announced the immediate availability of their two new Lyme IgG and Lyme IgM EIA kits for detection of antibodies against Lyme disease causing bacteria. The two assays give laboratories a more diverse arsenal of testing methodologies that allows them to achieve more reliable results. The assays are available immediately in the US. The separate IgG and IgM assays provide la